Drug design cycle

Nonetheless, the quahty of a screening Hbrary will improve if it is expanded by designed Hbraries that are optimized for small redundancy and high internal diversity. A noticeable increase of hit rates can also be expected if the library design is integrated in the drug design cycle. 

Fig. 3. Flowchart of the structure-based drug design cycle. The process, as well as technologies employed, varies between projects and between companies.

Fig. 26.2 The structure-based drug design cycle. The cycle can start either with a chemical lead, which is cocrystallized with the target protein, or with the structure of the target protein alone for de novo design. A number of cycles is usually necessary before one arrives at a suitable clinical candidate.

Both approaches outlined deliver information that is best used in cycles of medicinal chemistry/computer aided drug design in order to refine the compounds. 

Also in the 1980s, structure-based drug design (SBDD) underwent a similar cycle. Early proponents oversold what could be achieved through SBDD, thereby causing pharmaceutical companies to reconsider their investments when they discovered that SBDD too was no panacea for filling the drug discovery cornucopia with choice molecules for development. Nevertheless, SBDD was an important advance. 

Figure 13.1 The cycle of drug design, synthesis, and biological testing.

Rutenber E, Fauman EB, Keenan RJ, Ortiz de Montellano PR, Meng E, Kuntz ID, DeCamp DL, Salto R, Rose JR, Craik CS, Stroud RM. Structure of a nonpeptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design. J Biol Chem 1993 268 15343-6... 

The iterative structure-based drug design (SBDD) cycle (lead optimization)... 

The above three steps constitute one design cycle. It is often necessary to go through several iterations of the above cycle of structure determination, design, synthesis, and testing before a drug candidate emerges (Fig. 17.2). 

Figure 9.5 Malaria parasites have a complex life cycle, existing in many different forms between humans and mosquitoes. This offers a number of targets for drug design.

Effective structure-activity relationship (SAR) generation is at the centre of any medicinal chemistry campaign. Much work has been done to devise effective methods to explain and explore SAR data for medicinal chemistry teams to drive the design cycles within drug discovery projects (1). Recent work on SAR generation highlights the commonly observed discontinuity of SAR and bioactivity data, the so-called activity cliffs (2). This also emphasises the need to empirically determine SAR for each lead... 

A SBDD design should be confirmed by a later X-ray complex structure which in turn serves to initiate a cycle of iterative structural-based drug design (SBDD). SBDD starts from X-ray or NMR complex structure of ligand with protein and a design, if synthesized, validated, and confirmed by X-ray, creates a starting point for a new level of SBDD efforts. 

---